Capsid Inhibitors and Lenacapavir: A Mechanistic and Resistance Review
This narrative review consolidates the biology, resistance landscape, and pharmacokinetics of HIV capsid inhibitors, centering on lenacapavir for treatment and prevention, for pharmacists advising on antiretroviral selection and stewardship.
HIV capsid inhibitors could transform HIV treatment strategies.
HIV capsid inhibitors offer a novel mechanism for disrupting viral replication, crucial for treatment advancements. Lenacapavir shows promise in trials for treatment and long-acting pre-exposure prophylaxis (PrEP). Offers insights into capsid inhibitors as transformative in HIV treatment, but highlights ongoing challenges like resistance and accessibility. HIV capsid inhibitors represent a novel, promising addition to HIV therapy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Mahdi M, Lakatos B, Mótyán JA, Hoffka G, Tőzsér J
Citation:Mahdi M, Lakatos B, Mótyán JA, et al. HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances. PLoS pathogens. 2026;22(7):e1014361. doi:10.1371/journal.ppat.1014361
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.